Solifenacin	B:C1099677
in	O
the	O
Elderly	O
:	O
Results	O
of	O
an	O
Observational	O
Study	I:C1518527
Measuring	O
Efficacy	O
,	O
Tolerability	O
and	O
Cognitive	O
Effects	O
.	O

Solifenacin	O
in	O
the	O
Elderly	B:C0001792
:	O
Results	O
of	O
an	O
Observational	O
Study	I:C1518527
Measuring	O
Efficacy	O
,	O
Tolerability	O
and	O
Cognitive	O
Effects	O
.	O

Solifenacin	O
in	O
the	O
Elderly	O
:	O
Results	B:C2825142
of	O
an	O
Observational	O
Study	I:C1518527
Measuring	O
Efficacy	O
,	O
Tolerability	O
and	O
Cognitive	O
Effects	O
.	O

Solifenacin	O
in	O
the	O
Elderly	O
:	O
Results	O
of	O
an	O
Observational	B:C1518527
Study	I:C1518527
Measuring	O
Efficacy	O
,	O
Tolerability	O
and	O
Cognitive	O
Effects	O
.	O

The	O
study	B:C0008972
aimed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
solifenacin	O
in	O
older	O
patients	O
with	O
overactive	O
bladder	I:C0878773
(	O
overactive	O
bladder	I:C0878773
)	O
.	O

The	O
study	O
aimed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
solifenacin	B:C1099677
in	O
older	O
patients	O
with	O
overactive	O
bladder	I:C0878773
(	O
overactive	O
bladder	I:C0878773
)	O
.	O

The	O
study	O
aimed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
solifenacin	O
in	O
older	O
patients	O
with	O
overactive	B:C0878773
bladder	I:C0878773
(	O
overactive	O
bladder	I:C0878773
)	O
.	O

The	O
study	O
aimed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
solifenacin	O
in	O
older	O
patients	O
with	O
overactive	O
bladder	I:C0878773
(	O
overactive	B:C0878773
bladder	I:C0878773
)	O
.	O

Observational	O
data	O
on	O
patients	O
aged	O
≥	O
70	O
years	O
and	O
the	O
prescribed	O
flexible	O
dose	O
of	O
solifenacin	B:C1099677
for	O
overactive	O
bladder	I:C0878773
were	O
collected	O
at	O
294	O
offices	O
of	O
German	O
general	O
practitioners	I:C0017319
.	O

Observational	O
data	O
on	O
patients	O
aged	O
≥	O
70	O
years	O
and	O
the	O
prescribed	O
flexible	O
dose	O
of	O
solifenacin	O
for	O
overactive	B:C0878773
bladder	I:C0878773
were	O
collected	O
at	O
294	O
offices	O
of	O
German	O
general	O
practitioners	I:C0017319
.	O

Observational	O
data	O
on	O
patients	O
aged	O
≥	O
70	O
years	O
and	O
the	O
prescribed	O
flexible	O
dose	O
of	O
solifenacin	O
for	O
overactive	O
bladder	I:C0878773
were	O
collected	O
at	O
294	O
offices	B:C0031834
of	O
German	O
general	O
practitioners	I:C0017319
.	O

Observational	O
data	O
on	O
patients	O
aged	O
≥	O
70	O
years	O
and	O
the	O
prescribed	O
flexible	O
dose	O
of	O
solifenacin	O
for	O
overactive	O
bladder	I:C0878773
were	O
collected	O
at	O
294	O
offices	O
of	O
German	B:C1556085
general	O
practitioners	I:C0017319
.	O

Observational	O
data	O
on	O
patients	O
aged	O
≥	O
70	O
years	O
and	O
the	O
prescribed	O
flexible	O
dose	O
of	O
solifenacin	O
for	O
overactive	O
bladder	I:C0878773
were	O
collected	O
at	O
294	O
offices	O
of	O
German	O
general	B:C0017319
practitioners	I:C0017319
.	O

Baseline	O
and	O
week	O
12	O
data	O
included	O
type	O
and	O
severity	O
of	O
overactive	B:C0878773
bladder	I:C0878773
symptoms	O
,	O
adverse	O
events	I:C0877248
,	O
quality	O
of	O
life	O
,	O
and	O
change	O
in	O
cognitive	O
function	I:C0392335
per	O
Mini	O
Mental	I:C0451306
State	I:C0451306
Examination	I:C0451306
(	O
Mini	O
Mental	I:C0451306
State	I:C0451306
Examination	I:C0451306
)	O
.	O

Baseline	O
and	O
week	O
12	O
data	O
included	O
type	O
and	O
severity	O
of	O
overactive	O
bladder	I:C0878773
symptoms	B:C1457887
,	O
adverse	O
events	I:C0877248
,	O
quality	O
of	O
life	O
,	O
and	O
change	O
in	O
cognitive	O
function	I:C0392335
per	O
Mini	O
Mental	I:C0451306
State	I:C0451306
Examination	I:C0451306
(	O
Mini	O
Mental	I:C0451306
State	I:C0451306
Examination	I:C0451306
)	O
.	O

Baseline	O
and	O
week	O
12	O
data	O
included	O
type	O
and	O
severity	O
of	O
overactive	O
bladder	I:C0878773
symptoms	O
,	O
adverse	B:C0877248
events	I:C0877248
,	O
quality	O
of	O
life	O
,	O
and	O
change	O
in	O
cognitive	O
function	I:C0392335
per	O
Mini	O
Mental	I:C0451306
State	I:C0451306
Examination	I:C0451306
(	O
Mini	O
Mental	I:C0451306
State	I:C0451306
Examination	I:C0451306
)	O
.	O

Baseline	O
and	O
week	O
12	O
data	O
included	O
type	O
and	O
severity	O
of	O
overactive	O
bladder	I:C0878773
symptoms	O
,	O
adverse	O
events	I:C0877248
,	O
quality	O
of	O
life	O
,	O
and	O
change	O
in	O
cognitive	B:C0392335
function	I:C0392335
per	O
Mini	O
Mental	I:C0451306
State	I:C0451306
Examination	I:C0451306
(	O
Mini	O
Mental	I:C0451306
State	I:C0451306
Examination	I:C0451306
)	O
.	O

Baseline	O
and	O
week	O
12	O
data	O
included	O
type	O
and	O
severity	O
of	O
overactive	O
bladder	I:C0878773
symptoms	O
,	O
adverse	O
events	I:C0877248
,	O
quality	O
of	O
life	O
,	O
and	O
change	O
in	O
cognitive	O
function	I:C0392335
per	O
Mini	B:C0451306
Mental	I:C0451306
State	I:C0451306
Examination	I:C0451306
(	O
Mini	O
Mental	I:C0451306
State	I:C0451306
Examination	I:C0451306
)	O
.	O

Baseline	O
and	O
week	O
12	O
data	O
included	O
type	O
and	O
severity	O
of	O
overactive	O
bladder	I:C0878773
symptoms	O
,	O
adverse	O
events	I:C0877248
,	O
quality	O
of	O
life	O
,	O
and	O
change	O
in	O
cognitive	O
function	I:C0392335
per	O
Mini	O
Mental	I:C0451306
State	I:C0451306
Examination	I:C0451306
(	O
Mini	B:C0451306
Mental	I:C0451306
State	I:C0451306
Examination	I:C0451306
)	O
.	O

A	O
decrease	O
was	O
observed	O
in	O
all	O
overactive	B:C0878773
bladder	I:C0878773
symptoms	O
including	O
a	O
reduction	O
of	O
urinary	O
urgency	I:C0085606
and	O
micturition	O
,	O
each	O
by	O
4	O
episodes	O
per	O
24	O
h	O
.	O

A	O
decrease	O
was	O
observed	O
in	O
all	O
overactive	O
bladder	I:C0878773
symptoms	B:C1457887
including	O
a	O
reduction	O
of	O
urinary	O
urgency	I:C0085606
and	O
micturition	O
,	O
each	O
by	O
4	O
episodes	O
per	O
24	O
h	O
.	O

A	O
decrease	O
was	O
observed	O
in	O
all	O
overactive	O
bladder	I:C0878773
symptoms	O
including	O
a	O
reduction	O
of	O
urinary	B:C0085606
urgency	I:C0085606
and	O
micturition	O
,	O
each	O
by	O
4	O
episodes	O
per	O
24	O
h	O
.	O

A	O
decrease	O
was	O
observed	O
in	O
all	O
overactive	O
bladder	I:C0878773
symptoms	O
including	O
a	O
reduction	O
of	O
urinary	O
urgency	I:C0085606
and	O
micturition	B:C0042034
,	O
each	O
by	O
4	O
episodes	O
per	O
24	O
h	O
.	O

No	B:C0442739
change	I:C0442739
in	O
mean	O
MMSE	O
score	I:C2960235
s	O
was	O
apparent	O
at	O
week	O
12	O
.	O

No	O
change	I:C0442739
in	O
mean	O
MMSE	B:C2960235
score	I:C2960235
s	O
was	O
apparent	O
at	O
week	O
12	O
.	O

Adverse	B:C0877248
events	I:C0877248
and	O
treatment	O
discontinuations	I:C0457454
were	O
low	O
at	O
5.8	O
and	O
0.5	O
%	O
,	O
respectively	O
.	O

Adverse	O
events	I:C0877248
and	O
treatment	B:C0457454
discontinuations	I:C0457454
were	O
low	O
at	O
5.8	O
and	O
0.5	O
%	O
,	O
respectively	O
.	O

Solifenacin	B:C1099677
was	O
well	O
-	O
tolerated	O
while	O
overactive	O
bladder	I:C0878773
symptoms	O
declined	O
at	O
week	O
12	O
.	O

Solifenacin	O
was	O
well	O
-	O
tolerated	O
while	O
overactive	B:C0878773
bladder	I:C0878773
symptoms	O
declined	O
at	O
week	O
12	O
.	O

Solifenacin	O
was	O
well	O
-	O
tolerated	O
while	O
overactive	O
bladder	I:C0878773
symptoms	B:C1457887
declined	O
at	O
week	O
12	O
.	O

No	O
relevant	O
effect	O
of	O
solifenacin	B:C1099677
on	O
cognitive	O
function	I:C0392335
was	O
observed	O
in	O
this	O
elderly	O
population	I:C0001792
.	O

No	O
relevant	O
effect	O
of	O
solifenacin	O
on	O
cognitive	B:C0392335
function	I:C0392335
was	O
observed	O
in	O
this	O
elderly	O
population	I:C0001792
.	O

No	O
relevant	O
effect	O
of	O
solifenacin	O
on	O
cognitive	O
function	I:C0392335
was	O
observed	O
in	O
this	O
elderly	B:C0001792
population	I:C0001792
.	O

